Strategic Partnerships Alveolus Bio develops inhaled live biotherapeutics for IPF, COPD, and NCFBE, presenting opportunities for co development, clinical trials, and eventual commercialization with larger pharmaceutical companies that want differentiated pulmonary therapies.

Licensing Opportunities With a preclinical stage pipeline, there is potential to out license programs or engage in research collaborations with biotech or pharma partners to share risk and accelerate development timelines.

Asia Collaboration Investment from Shilpa Medicare suggests readiness for Asia Pacific partnerships; explore co development, manufacturing, or distribution collaborations and leverage investor network to enter regional markets.

Outsourcing Model As a small team, Alveolus Bio can leverage pulmonology CROs, inhalation formulation specialists, and CDMOs to advance preclinical work and interim clinical stages while expanding capacity.

Differentiated Delivery The inhaled distal lung delivery approach potentially improves efficacy and reduces adverse effects; position as a unique value proposition to device manufacturers and business development teams seeking differentiated pulmonary therapies.